Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery

Figure 4

Amikacin concentration in lungs and kidneys after its i.v. and pulmonary administration as (a) SLNs and (b) free drug (𝑛=3, ^∗𝑃<0.05, differences between different times in lung concentrations are significant after pulmonary administration of SLNs; ^$𝑃<0.05, lung concentrations in each time are significantly different from kidney concentration after pulmonary administration of SLNs; ^∧𝑃<0.05, kidney concentrations are different from lung concentration after i.v. administration of SLNs; ^#𝑃<0.05, differences in lung concentration are significant between i.v. and pulmonary routes).

(a)

(b)